{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:59:36Z","timestamp":1760623176991,"version":"3.37.3"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1136\/annrheumdis-2020-218713","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T21:20:39Z","timestamp":1597267239000},"page":"e191-e192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials \u2013 a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al"],"prefix":"10.1016","volume":"81","clinical-trial-number":[{"clinical-trial-number":"isrctn40580903","registry":"10.18810\/isrctn"}],"author":[{"given":"Milena","family":"Gianfrancesco","sequence":"first","affiliation":[]},{"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[]},{"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3156-3418","authenticated-orcid":false,"given":"Philip C","family":"Robinson","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2020-218713_bib1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2020-218713_bib2","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1136\/annrheumdis-2020-218528","article-title":"Compassionate use of tocilizumab in severe COVID-19 with Hyperinflammation prior to advent of clinical trials \u2013 a real-world district general Hospital experience","volume":"81","author":"Khan","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2020-218713_bib3","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1136\/annrheumdis-2020-218609","article-title":"Comment on \u2018Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry\u2019 by Gianfrancesco M et al","volume":"81","author":"Andreica","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2020-218713_bib4","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1136\/annrheumdis-2020-218737","article-title":"COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs","volume":"81","author":"Ansarin","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2020-218713_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2020-218479","article-title":"Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the chiC study","volume":"79","author":"Ramiro","year":"2020","journal-title":"Ann Rheum Dis"},{"author":"Roche","key":"10.1136\/annrheumdis-2020-218713_bib6"},{"author":"Regeneron & Sanofi","key":"10.1136\/annrheumdis-2020-218713_bib7"},{"key":"10.1136\/annrheumdis-2020-218713_bib8","article-title":"An inflammatory cytokine signature helps predict COVID-19 severity and death","author":"Del Valle","year":"2020","journal-title":"medRxiv"},{"key":"10.1136\/annrheumdis-2020-218713_bib9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2020-218713_bib10","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","article-title":"Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2018","volume":"79","author":"D'Silva","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724184567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724184567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2020-218713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:01:05Z","timestamp":1737248465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724184567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0003496724184567"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2020-218713","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials \u2013 a real-world district general hospital experience' by Khan et al, 'Comment on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al' by Andreica et al and 'COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs' by Ansarin et al","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2020-218713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2020-218609","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2020-218737","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2020-218528","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}